WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Tuesday that it has been included in the FTSE4Good Index Series in recognition of its outstanding sustainability performance, for the sixth consecutive year.

Launched in 2001 by FTSE Russell (now part of the London Stock Exchange Group), the FTSE4Good Index Series is a family of equity indices designed to measure the performance of companies demonstrating strong Environmental, Social, and Governance (ESG) practices. It serves as a benchmark for investors seeking to align their portfolios with sustainability goals.

This year, WuXi Biologics ranked among the top 4% of the global health care sector in ESG performance, and was highlighted for its performance across key areas, including corporate governance, ethics, labour standards, environmental management, and sustainability strategy.

WuXi Biologics integrates sustainability into its operations management, technology innovation, and supply chain system.